( e indicate thatour VLP vaccines have t...)Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data,Show,Health

e indicate that our VLP vaccines have the potential to provide protection against various strains of avian influenza," Dr. Bright said. "We are particularly encouraged by these ferret data and look forward to evaluating the immunogenicity of our H5N1 VLP vaccine in the clinic later this year."

The study was conducted in collaboration with Dr. Terrence Tumpey of the Center for Disease Control and Prevention's Influenza Division based in Atlanta, GA. As part of the study, Novavax also evaluated its proprietary Novasome adjuvant with both the H9N2 VLP vaccine and a recombinant hemagglutanin antigen vaccine. Both vaccines combined with adjuvant were shown to provide protection in mice. Adjuvants are used to improve the efficacy of vaccines and may help reduce the dosage required for protection in a pandemic setting.

The study appears in the online version of the peer-reviewed journal Vaccine and is currently available at http://tinyurl.com/2q9wla. The print edition will be published shortly.

About Novavax

Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

Forward Looking Statements

Statements herein relating to future financial or business performance, cond
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
2. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
10. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
11. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus